News

Pharmamar’s new  candidate avails
Enlarge image

OncologySpain

Pharmamar’s new candidate avails

03.10.2012 - Clinical data presented at a Congress in Vienna shows that a new Pharmamar drug could step up to the success of its paragon Yondelis.

Pharmamar S.A. from Colmenar Viejo is part of Spain’s largest biotech Zeltia S.A. It is known for its marine tunicate-derived anti-cancer drug Yondelis. But there is another potentially marketable drug named PM01183 (lurbinectedin) in the pipeline. On 30 September, new clinical data was presented at the 37th Congress of the European Society of Molecular Oncology (ESMO) in Vienna. Results from the first part of a two-stage Phase II study in patients with platinum-resistant or refractory ovarian cancers were well-perceived, where a confirmed response to the treatment was observed in 6 out of 22 patients. Moreover, the disease had only progressed in 6 patients at the first evaluation, which means that the tumour remained stable in the remaining 10 patients (disease control rate: 73%). The drug showed no toxicity-related problems. The second stage was launched in April with the enrolment of 60 additional patients, who will be randomised to either the PM01183 arm or the active comparator arm where GSK’s topotecan is given.

Other indications where PM01183’s potential is scrutinised include non-small-cell lung carcinoma and breast cancer. Data of a Phase Ib study also presented at the meeting suggest that a combination of PM01183 with the nucleoside analogue gemcitabine improves the anti-tumour activities in the first mentioned indication when compared to treatments with each drug alone. The latter indication is dealt with in a Phase II study with metastatic breast cancer (MBC) patients which started in June this year. Here, patients are stratified into one group where the women have certain deleterious germline mutations in BRCA1/2 and another with woman without such mutations. Pharmamar wants to show that PM01183 works for BRCA 1/2-associated MBCs.

Pharmamar also tries to widen the scope of Yondelis, the first cancer medication ever to be developed in Spain. Moving from 2nd line to 1st line indications Yondelis (trabectedin) is currently under investigation for its strength to fight non-operable and/or metastatic soft tissue sarcomas. In the trial named GEIS-20 standard doxorubicin treatment is compared against a doxorubicin-trabectedin-combination. Results of the Phase II, open label, randomised study with 182 patients are expected in Q4/12.

© eurobiotechnews.eu/ml

http://www.european-biotechnology-news.com/news/news/2012-04/pharmamars-new-candidate-avails.html

Open InnovationFrance

03.05.2016 Ipsen is strengthening its ties to long-time development partner Oncodesign, a Dijon-based cancer treatment biotech. The French pharma is handing over the pre-clinical pharmacology for its oncology research programmes to Oncodesign.

FinancingSwitzerlandEU

29.04.2016 Swiss bank Group UBS has raised US$471m (€412m) for the UBS Oncology Impact Fund, which was set up to invest in early-stage cancer treatments. The money raised by the fund, nearly half of which comes from investors in Asia, is the largest amount ever raised for such a cancer investment fund.

Industry reportGermany

27.04.2016 More revenue, more jobs, more financing, more R&D expenditure – all signs point towards sustainable growth in the German biotech sector. These are the results of the most recent company survey 2016, published by biotechnologie.de. The report was once again conducted alongside the biotech standards defined by the organisation for economic cooperation and development (OECD).

Clinical ResearchFrancePortugal

21.04.2016 An expert panel’s final report on the fatal drug trial earlier this year in France states that the death of one of the participants was most likely caused by the drug’s toxicity and not by any violation of the rules.

Immuno-oncologyNetherlandsBelgium

21.04.2016 For up to US$685m (€606m), Dutch ArgenX has outlicensed its human antibody programme ARGX-115 to AbbVie. The pre-clinical immuno-oncology candidate targets a protein believed to contribute to immunosuppressive effects of T-cells.

RegulatorySwitzerlandEU

20.04.2016 The US government is forking out up to US$100m to get Basilea Pharmaceutica’s broad-spectrum antibiotic ceftobiprole on the US market. In the EU, ceftobiprole is already available.

Immuno-oncologyUK

19.04.2016 British drug developer Heptares Therapeutics and mAb maker Kymab Ltd have partnered up in yet another immuno-oncology collaboration. The companies plan to discover antibody meds targeting a superfamily of receptors.

FinancingSwitzerlandFranceEUGermanyDenmark

15.04.2016 Not every company is put off by the current stock market climate. Swiss biopharma company GeNeuro has gone public at Euronext Paris, raising €33m in the process. Others, meanwhile, have to find different ways to raise money.

Event ReviewSwitzerlandBelgiumEU

13.04.2016 Despite political disturbances, 2015 was a good year for the biotech scene in Switzerland. Net sales increased by 5.1% to CHF5,133m and 400 additional people found jobs in the sector. As usual, the new numbers were presented at the annual Swiss Biotech Day – which set new records as well.

FinancingGermanyNetherlandsEU

12.04.2016 German-Dutch life science investment specialist Forbion Capital Partners has raised more than €180m for its venture capital fund Forbion Capital Fund III. Once more the money will primarily go to European start-ups.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

München

BioVaria 2016

Berlin (GER)

XIV. BIONNALE 2016

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BIOTIE THERAPEUTICS (FI)0.27 EUR92.86%
  • THERAMETRICS (CH)0.03 CHF50.00%
  • PLETHORA (UK)3.38 GBP12.67%

FLOP

  • EVOCUTIS (UK)0.05 GBP-16.67%
  • BAVARIAN NORDIC (D)33.10 EUR-8.56%
  • SARTORIUS (D)244.55 EUR-6.30%

TOP

  • SYNAIRGEN (UK)35.50 GBP47.9%
  • BIOFRONTERA (D)3.19 EUR36.9%
  • SWEDISH ORPHAN BIOVITRUM (S)15.24 USD27.5%

FLOP

  • EVOCUTIS (UK)0.05 GBP-28.6%
  • SERODUS (N)1.48 NOK-27.5%
  • NEUROVIVE PHARMACEUTICAL AB (S)6.25 SEK-26.5%

TOP

  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • KARO BIO (S)29.00 SEK1833.3%
  • NICOX (F)8.59 EUR352.1%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)6.25 SEK-88.0%
  • BB BIOTECH (D)45.22 EUR-83.5%
  • CYTOS (CH)0.26 CHF-80.3%

No liability assumed, Date: 03.05.2016